Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$55.14 USD
-3.62 (-6.16%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $55.08 -0.06 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NKTR 55.14 -3.62(-6.16%)
Will NKTR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
Other News for NKTR
NKTR forms Bearish Engulfing on September 20
NKTR makes New 52 Week Closing High on September 19
Analysts Are Bullish on These Healthcare Stocks: Edwards Lifesciences (EW), Nektar Therapeutics (NKTR)
Oppenheimer Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NKTR), Embecta Corporation (EMBC) and Replimune Group (REPL)